Vanderbilt Ingram Cancer Center, Division of Heamology & Medical Oncology, Nashville, TN 37232, USA.
Expert Opin Investig Drugs. 2011 Apr;20(4):441-5. doi: 10.1517/13543784.2011.553185.
Small cell lung cancer (SCLC) will account for 25,000 to 32,000 new lung cancer cases in the USA in 2010. Current treatmenta pproaches include platinum-based chemotherapy and etoposide with or without radiation therapy depending on stage and performance status. Five-year survival is approximately 25% for patients with limited stage disease and 1 -- 2% for patients with extensive stage disease and has noti mproved in almost two decades.
This article reviews the results of recent clinical trials that have evaluated targeted agents and novel cytotoxic agents alone or in combination with standard chemotherapy in the treatment of patients with SCLC.
The lack of a targeted approach to the treatment of patients with SCLC has led investigators to evaluate a multitude of agents with overwhelmingly negative results. A more systematic approach to clinical trials in patients is needed to improve outcomes for patients with this disease.
2010 年，美国将有 2.5 万至 3.2 万例新的肺癌病例为小细胞肺癌（SCLC）。目前的治疗方法包括铂类为基础的化疗和依托泊苷，根据分期和体能状态选择是否联合放射治疗。局限期疾病患者的 5 年生存率约为 25%，广泛期疾病患者的 5 年生存率约为 1%至 2%，近二十年来几乎没有改善。
本文回顾了最近的临床试验结果，这些试验评估了单一靶向药物和新型细胞毒性药物以及标准化疗联合治疗 SCLC 患者的疗效。
由于缺乏针对 SCLC 患者的靶向治疗方法，研究人员评估了大量药物，但结果均令人失望。需要对患者进行更系统的临床试验，以改善此类患者的预后。
